{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:15:14Z","timestamp":1777853714263,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Intensive Care Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Catecholamines are first-line vasopressors for hemodynamic support in distributive shock but are associated with adverse effects, which may be mitigated with noncatecholamine vasopressors. Angiotensin II (ATII) is a noncatecholamine vasopressor recently approved for the management of distributive shock, but limited data support its clinical utility. The purpose of this study was to describe our institution\u2019s usage of ATII including patient outcomes (eg, response to therapy, safety profile).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Patients who received ATII at our institution were included. Patient demographics, degree of concordance with institutional ATII use guidelines, safety profile of ATII, and response to therapy (1 and 3 hours after ATII initiation) were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 16 patients received ATII for distributive shock. The median Sequential Organ Failure Assessment score at the time of ATII initiation was 16.5 (interquartile range: 15.8-20.0). Fourteen (87.5%) patients met institutional guidelines for ATII use; 10 (62.5%) and 8 (50.0%) patients met our definition for response at 1 and 3 hours, respectively. No patients developed thrombotic or infectious complications after receiving ATII.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this cohort, ATII appears to be well tolerated in patients with a high predicted mortality. Future studies evaluating the clinical efficacy of ATII are needed to determine its role in the management of distributive shock.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0885066619872720","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T23:54:48Z","timestamp":1567554888000},"page":"1490-1496","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["A Retrospective Review of Angiotensin II Use in Adult Patients With Refractory Distributive Shock"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0066-6235","authenticated-orcid":false,"given":"Adrian","family":"Wong","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, MCPHS University, Boston, MA, USA"},{"name":"Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afrah","family":"Alkazemi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. Mary","family":"Eche","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille R.","family":"Petri","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Sarge","sequence":"additional","affiliation":[{"name":"Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5541-5209","authenticated-orcid":false,"given":"Michael N.","family":"Cocchi","sequence":"additional","affiliation":[{"name":"Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA"},{"name":"Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"key":"bibr1-0885066619872720","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-1106"},{"key":"bibr2-0885066619872720","doi-asserted-by":"publisher","DOI":"10.4161\/viru.27372"},{"issue":"3","key":"bibr3-0885066619872720","first-page":"304","volume":"43","author":"Rhodes A","year":"2017","journal-title":"Crit Care Med"},{"key":"bibr4-0885066619872720","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907118"},{"key":"bibr5-0885066619872720","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2014.1566"},{"key":"bibr6-0885066619872720","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00287.2006"},{"key":"bibr7-0885066619872720","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704154"},{"key":"bibr8-0885066619872720","volume-title":"RED BOOK Online. Micromedex Healthcare Series [Database Online]","author":"Active Ingredient: Angiotensin II","year":"2019"},{"key":"bibr9-0885066619872720","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90129-5"},{"key":"bibr10-0885066619872720","doi-asserted-by":"publisher","DOI":"10.1007\/BF01709751"},{"key":"bibr11-0885066619872720","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-198510000-00009"},{"key":"bibr12-0885066619872720","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2016.11.036"},{"key":"bibr13-0885066619872720","first-page":"654708","volume":"2013","author":"Bassi E","year":"2013","journal-title":"Crit Care Res Pract"},{"key":"bibr14-0885066619872720","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0000000000000341"},{"key":"bibr15-0885066619872720","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000003092"},{"key":"bibr16-0885066619872720","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-019-0536-5"},{"key":"bibr17-0885066619872720","unstructured":"Rose M. Center for Drug Evaluation and Research. Application number: 209360Orig1s000: Summary review. Food and Drug Administration website. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209360Orig1s000SumR.pdf. Updated December 21, 2017. Accessed July 14, 2019."},{"key":"bibr18-0885066619872720","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-018-2202-y"},{"key":"bibr19-0885066619872720","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067373"},{"key":"bibr20-0885066619872720","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000002441"},{"key":"bibr21-0885066619872720","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.95.08111838"},{"key":"bibr22-0885066619872720","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2018.12.007"}],"container-title":["Journal of Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0885066619872720","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0885066619872720","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0885066619872720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:56:18Z","timestamp":1777503378000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0885066619872720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1177\/0885066619872720"],"URL":"https:\/\/doi.org\/10.1177\/0885066619872720","relation":{},"ISSN":["0885-0666","1525-1489"],"issn-type":[{"value":"0885-0666","type":"print"},{"value":"1525-1489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,3]]}}}